Repatha drug class
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest Repatha (evolocumab) is a PCSK9 inhibitor used to treat primary hypercholesterolemia, mixed dyslipidemia, and homozygous familial hypercholesterolemia.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Evolocumab (Repatha): A Comprehensive Overview of Its Drug Class
Introduction to Evolocumab (Repatha)
Evolocumab, marketed under the brand name Repatha, is a fully human monoclonal antibody developed by Amgen. It has been approved for the treatment of hypercholesterolemia, particularly in patients who have not achieved desired cholesterol levels with statins and other lipid-lowering therapies . This article delves into the drug class of Evolocumab, its mechanism of action, clinical applications, and efficacy.
Drug Class: PCSK9 Inhibitors
Mechanism of Action
Evolocumab belongs to a novel class of lipid-regulating drugs known as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. PCSK9 is a protein that plays a crucial role in the regulation of low-density lipoprotein receptors (LDL-R) on liver cells. By binding to PCSK9, Evolocumab prevents the degradation of LDL-R, thereby increasing the number of receptors available to clear LDL-cholesterol (LDL-C) from the bloodstream . This mechanism significantly reduces LDL-C levels in patients .
Administration and Dosage
Evolocumab is administered via subcutaneous injection, typically at a dosage of 140 mg every two weeks or 420 mg once monthly . This flexible dosing schedule allows for tailored treatment plans based on patient needs and preferences.
Clinical Applications
Hypercholesterolemia and Dyslipidemia
Evolocumab is primarily used to treat various forms of hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and mixed dyslipidemia. It is often prescribed as an adjunct to diet and maximally tolerated statin therapy . For patients who are statin-intolerant or cannot achieve LDL-C targets with statins alone, Evolocumab offers a valuable alternative .
Cardiovascular Risk Reduction
While the primary focus of Evolocumab is on lowering LDL-C levels, it also plays a role in reducing the risk of atherosclerotic cardiovascular disease. However, its long-term impact on cardiovascular outcomes is still under investigation.
Efficacy and Safety
Clinical Trials and Efficacy
Evolocumab has demonstrated significant efficacy in reducing LDL-C levels across multiple clinical trials. In 12-week phase III trials, it was more effective than placebo and ezetimibe, achieving LDL-C reductions of up to 60% . These results were consistent whether Evolocumab was used as monotherapy, in combination with statins, or in statin-intolerant patients .
Safety Profile
Evolocumab has been well-tolerated in clinical studies, with a safety profile comparable to placebo. Common side effects include injection site reactions, nasopharyngitis, and upper respiratory tract infections . Importantly, Evolocumab does not appear to adversely affect cognitive function, a concern with some lipid-lowering therapies.
Conclusion
Evolocumab (Repatha) represents a significant advancement in the management of hypercholesterolemia and dyslipidemia. As a PCSK9 inhibitor, it offers a potent mechanism for lowering LDL-C levels, particularly in patients who are unable to achieve their cholesterol targets with statins alone. With its proven efficacy and favorable safety profile, Evolocumab is a valuable addition to the therapeutic arsenal against cardiovascular disease.
Sources and full results
Most relevant research papers on this topic
